| Literature DB >> 30087603 |
Robyn Human1, Michelle Henry1,2, W Jake Jacobs3, Kevin G F Thomas1.
Abstract
Activation of the hypothalamic-pituitary-adrenal (HPA) axis (as might occur, for example, when the organism encounters a threat to allostatic balance) leads to the release of cortisol into the bloodstream and, ultimately, to altered neural functioning in particular brain regions (e.g., the prefrontal cortex (PFC)). Although previous studies suggest that exposure to acute psychosocial stress (and hence, presumably, elevation of circulating cortisol levels) enhances male performance on PFC-based working memory (WM) tasks, few studies have adequately investigated female performance on WM tasks under conditions of elevated cortisol. Hence, we compared associations between elevated (relative to baseline) levels of circulating cortisol and n-back performance in a South African sample (38 women in the late luteal phase of their menstrual cycle, 38 men). On Day 1, participants completed practice n-back tasks. On Day 2, some completed the Trier Social Stress Test (TSST), whereas others experienced a relaxation period, before completing 1-back and 3-back tasks. We measured self-reported anxiety and salivary cortisol at baseline, post-manipulation and end of session. We reconstituted group assignment so that all women with elevated cortisol were in one group (EC-Women; n = 17), all men with elevated cortisol were in another (EC-Men; n = 19), all women without elevated cortisol were in a third (NoEC-Women; n = 21), and all men without elevated cortisol were in a fourth (NoEC-Men; n = 19) group. Analyses suggested this reconstitution was effective: in EC, but not NoEC, groups cortisol levels rose significantly from baseline to post-manipulation. Analyses of n-back data detected significant relations to task load (i.e., better performance on 1-back than on 3-back tasks), but no significant relations to sex, performance accuracy/speed, or cortisol variation. The data patterns are inconsistent with reports describing sex differences in effects of stress on WM performance. We speculate that cross-study methodological differences account for these inconsistencies, and, particularly, that between-study variation in the magnitude of baseline cortisol levels might affect outcomes. For instance, diurnal cortisol rhythms of South African samples might have flatter curves, and lower baseline values, than predominantly Caucasian samples from the United States and western Europe due to greater prenatal and lifetime stress, more socioeconomic disadvantage and faster ancestral life history (LH) strategies. We describe ways to disconfirm this hypothesis, and urge further cross-national research exploring these possibilities.Entities:
Keywords: Trier Social Stress Test (TSST); cortisol; psychological stress; sex differences; working memory
Year: 2018 PMID: 30087603 PMCID: PMC6066520 DOI: 10.3389/fnhum.2018.00299
Source DB: PubMed Journal: Front Hum Neurosci ISSN: 1662-5161 Impact factor: 3.169
Reasons recruited participants were excluded from final data analysis (n = 26).
| Number excluded | ||
|---|---|---|
| Reason for exclusion | Men | Women |
| BDI-II score ≥ 29 | 3 | 3 |
| Began menstruation on Day 2 of the study | N/A | 3 |
| Did not arrive for Day 2 | 2 | 3 |
| Accepted ethical right to withdraw from the study | 0 | 1 |
| Did not meet criterion on Day 1 | 2 | 0 |
| More than 1 day out of late luteal phase during Day 2 | N/A | 7 |
| Unusual baseline cortisol level | 0 | 1 |
| Cortisol data lost | 0 | 1 |
| Total excluded | 7 | 19 |
Note. BDI-II, Beck Depression Inventory—Second Edition.
Figure 1Day 2 experimental procedures. CORT, cortisol levels; STAI, State-Trait Anxiety Inventory; TSST, Trier Social Stress Test. Part (A) shows the overall procedure, while Part (B) shows details of the experimental manipulation.
Between-group comparisons: participant age and self-reported depression and anxiety (N = 76).
| Group | |||||||
|---|---|---|---|---|---|---|---|
| Measure | EC-Women ( | EC-Men ( | NoEC-Women ( | NoEC-Men ( | ESE | ||
| Age | 19.12 (1.11) | 19.84 (1.89) | 18.95 (1.16) | 18.89 (0.99) | 2.05 | 0.12 | 0.08 |
| BDI-II | 13.06 (6.55) | 9.89 (6.13) | 12.43 (6.18) | 10.42 (5.31) | 1.19 | 0.32 | 0.05 |
| STAI-Trait | 40.94 (9.15) | 37.37 (5.98) | 43.67 (10.97) | 39.89 (9.64) | 1.61 | 0.19 | 0.06 |
Note. Data presented are means with standard deviations in parentheses. ESE, effect size estimate (in this case, β.
Descriptive statistics: self-report and physiological measures (N = 76).
| Group | ||||
|---|---|---|---|---|
| Measure | EC-Women ( | EC-Men ( | NoEC-Women ( | NoEC-Men ( |
| STAI-State | ||||
| STAIB | 36.94 (8.50) | 34.58 (6.69) | 37.43 (10.97) | 34.58 (11.78) |
| STAI1 | 45.53 (11.73) | 39.16 (12.31) | 36.43 (11.60) | 30.68 (12.43) |
| STAI2 | 32.94 (7.20) | 29.26 (6.83) | 33.00 (8.33) | 31.05 (6.56) |
| Cortisol | ||||
| CORTB | 1.08 (1.06) | 1.96 (2.04) | 1.97 (2.28) | 2.57 (2.86) |
| CORT1 | 4.11 (2.89) | 7.03 (4.65) | 1.55 (1.90) | 1.82 (2.23) |
| CORT2 | 1.30 (0.81) | 2.65 (2.35) | 1.16 (1.37) | 1.55 (1.97) |
Note. Data presented are means with standard deviations in parentheses. STAI, State-Trait Anxiety Inventory. Cortisol levels are measured in nanomoles per liter (nmol/l). Where cortisol levels for a participant were measured at <0.50 nmol/l, 0.45 nmol/l was used as an estimate.
Figure 2Changes in cortisol levels across the Day 2 experimental procedures. Error bars represent standard deviations. Data for elevated cortisol (EC) groups are presented separately from those for NoEC groups to allow easier viewing of the magnitude of error bars. CORTB, cortisol at baseline; CORT1, cortisol at the first post-manipulation measurement point (i.e., 5 min post-manipulation); CORT2, cortisol at the second post-manipulation measurement point (i.e., 45 min post-manipulation).
Descriptive statistics: Day 1 n-back trials to criterion (N = 76).
| Group | ||||
|---|---|---|---|---|
| Task load/Trial number | EC-Women ( | EC-Men ( | NoEC-Women ( | NoEC-Men ( |
| 0-back | ||||
| One | 16 | 18 | 21 | 18 |
| Two | 1 | 1 | 0 | 1 |
| 1-back | ||||
| One | 14 | 18 | 19 | 15 |
| Two | 2 | 1 | 2 | 4 |
| Three | 1 | 0 | 0 | 0 |
| 3-back | ||||
| One | 11 | 17 | 17 | 13 |
| Two | 5 | 2 | 2 | 5 |
| Three | 1 | 0 | 1 | 1 |
| Four | 0 | 0 | 1 | 0 |
Note. Data presented indicate number of people who reached criterion on the indicated trial.
Descriptive statistics: Day 2 n-back performance (N = 76).
| Group | |||||
|---|---|---|---|---|---|
| Measure | EC-Women ( | EC-Men ( | NoEC-Women ( | NoEC-Men ( | |
| Block 1 | |||||
| CIS | 1-back | 95.24 (6.94) | 95.74 (6.53) | 94.79 (5.61) | 96.49 (3.49) |
| 3-back | 87.50 (9.97)a | 83.21 (8.15) | 82.31 (14.92) | 87.47 (8.58) | |
| MRT | 1-back | 581.74 (130.20) | 681.72 (203.05) | 560.83 (175.51) | 606.28 (155.64) |
| 3-back | 799.33 (239.58)a | 912.45 (359.02) | 791.00 (284.22) | 853.54 (839.38) | |
| Block 2 | |||||
| CIS | 1-back | 93.00 (7.36) | 94.74 (4.73) | 95.01 (6.30) | 92.98 (15.90) |
| 3-back | 82.63 (10.10) | 79.95 (13.05) | 83.67 (11.23) | 79.70 (14.10) | |
| MRT | 1-back | 621.57 (152.20) | 704.01 (212.36) | 593.26 (173.14) | 585.08 (134.99) |
| 3-back | 848.25 (249.75) | 900.66 (382.67) | 807.83 (265.17) | 916.83 (300.42) | |
| Block 3 | |||||
| CIS | 1-back | 95.24 (4.76) | 93.99 (7.91) | 94.79 (6.55) | 92.48 (7.33) |
| 3-back | 88.24 (12.04) | 84.96 (11.91) | 82.31 (12.79) | 86.47 (9.43) | |
| MRT | 1-back | 619.26 (140.62) | 659.08 (206.56) | 602.37 (193.02) | 643.44 (183.56) |
| 3-back | 767.63 (225.19) | 772.31 (330.40) | 775.22 (317.99) | 835.55 (295.45) | |
| Block 4 | |||||
| CIS | 1-back | 93.48 (6.02) | 94.24 (7.87) | 92.52 (9.59) | 93.74 (11.88) |
| 3-back | 84.59 (9.45) | 86.72 (11.10) | 78.47 (19.66) | 79.45 (14.38) | |
| MRT | 1-back | 598.36 (97.97) | 678.71 (236.25) | 573.72 (156.81) | 620.00 (170.51) |
| 3-back | 802.66 (220.58) | 807.55 (325.61) | 748.32 (198.36) | 878.23 (317.77) | |
Note. Data presented are means, with standard deviations in parentheses. CIS, correctly identified stimuli; MRT, mean reaction time (measured in milliseconds). .
Figure 3Mean Reaction Time (MRT), for all participants, on the sets of 1-back and 3-back trials.